Emotional Impact – Short Form (ASCQ-Me)

Abstract

The Adult Sickle Cell Quality of Life Measurement System (ASCQ-Me) – Emotional Impact Short Form is a targeted, psychometrically validated patient-reported outcome measure (PROM) developed under the auspices of the National Heart, Lung, and Blood Institute (NHLBI). Designed to quantify the specific psychological and emotional burden experienced by adults living with sickle cell disease (SCD), this 5-item instrument addresses key affective domains including health-related hopelessness, anxiety regarding future disease trajectory, loneliness, depression, and functional frustration. Grounded in modern item response theory (IRT) and classical test theory, the measure utilizes a 7-day recall period. Items 1 and 2 are scored on a 5-point frequency scale (1 = Never to 5 = Always), whereas items 3, 4, and 5 evaluate emotional severity (1 = Not at all to 5 = Very). Raw scale scores are summed and transformed into standardized T-score metrics with a mean of 50 and a standard deviation of 10, normed against an adult SCD reference population. Within this scoring rubric, higher T-scores reflect superior health-related quality of life—denoting lower emotional impact and reduced psychological burden. Extensive validation studies demonstrate excellent internal consistency reliability (α ≥ .88 to .91; IRT marginal reliability ≥ .85), robust unidimensionality via confirmatory factor analysis (CFI > .98, RMSEA < .06), and strong convergent and discriminant validity with established measures such as PROMIS, the SF-36 Mental Component Summary, and objective SCD severity indicators. The ASCQ-Me Emotional Impact Short Form represents an efficient, clinically responsive instrument for epidemiological research, clinical trials, and routine comprehensive hematological care.

Keywords

Sickle cell disease, ASCQ-Me, Health-Related Quality of Life, Emotional Impact, Patient-Reported Outcome Measures, Item Response Theory, Depression, Health Anxiety, Psychological Burden, Chronic Illness

Authors

The Adult Sickle Cell Quality of Life Measurement System (ASCQ-Me) was conceived, developed, and field-tested by a specialized academic and clinical consortium sponsored by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH). Key investigators and psychometricians who spearheaded the development and psychometric validation of the ASCQ-Me emotional impact domain include:

• San Keller, Ph.D. – American Institutes for Research (AIR), Chapel Hill, NC, USA. Principal investigator and lead psychometrician responsible for item bank calibration, qualitative cognitive interviewing, and IRT modeling.
• David Yang, Ph.D. – American Institutes for Research, psychometric modeling and statistical programming.
• Marsha J. Treadwell, Ph.D. – Department of Hematology/Oncology, UCSF Benioff Children’s Hospital Oakland, Oakland, CA, USA. Leading clinical psychologist specializing in sickle cell disease psychosocial care and developmental outcomes.
• Carlton D. Dampier, M.D. – Department of Pediatrics, Emory University School of Medicine and Children’s Healthcare of Atlanta, Atlanta, GA, USA. Renowned pediatric and adult hematologist and clinical investigator in SCD pain and functional outcomes.
• ASCQ-Me Field Testing Steering Committee – Comprising multidimensional teams across Duke University, the University of North Carolina at Chapel Hill, Johns Hopkins University, and the Medical College of Wisconsin.

Purpose

The ASCQ-Me Emotional Impact Short Form was developed to address a longstanding measurement gap in hematology: the absence of a disease-specific, psychometrically rigorous instrument capable of quantifying the unique psychological toll of living with adult sickle cell disease. While generic health-related quality of life (HRQoL) tools—such as the Medical Outcomes Study 36-Item Short Form Survey (SF-36) or generic PROMIS measures—capture broad affective distress, they systematically fail to differentiate generalized neurotic distress from negative affect directly attributable to the unpredictable, life-threatening complications of SCD.

Sickle cell disease is characterized by chronic hemolytic anemia, unpredictable and excruciating vaso-occlusive crises (VOC), progressive end-organ damage, cognitive complications, systemic microvascular ischemia, and reduced life expectancy. Concurrently, adults with SCD navigate profound systemic challenges, including healthcare-associated racial bias, stigmatization as “drug-seeking” during acute pain management, vocational disruption, and social disenfranchisement. Consequently, psychological morbidity—particularly clinical depression, illness-specific anxiety, demoralization, and existential frustration—is markedly higher in this population than in the general population.

The primary clinical and research objectives of the Emotional Impact Short Form include:

• Attributional Precision: Assessing emotional distress explicitly attributed by the patient to their physical health status, thereby disentangling health-induced despair from premorbid or unrelated existential distress.
• Screening and Clinical Monitoring: Serving as an ultra-brief (5-item), low-burden screening mechanism within comprehensive sickle cell centers, outpatient hematology clinics, and transition programs to detect clinically actionable psychological suffering.
• Comparative Clinical Effectiveness Research: Providing a sensitive, standardized endpoint for pharmacological trials (e.g., disease-modifying therapies such as hydroxyurea, L-glutamine, crizanlizumab, voxelotor, or curative gene therapies) and behavioral interventions (e.g., cognitive behavioral therapy, mindfulness-based stress reduction).
• Health Disparity and Psychosocial Investigation: Facilitating longitudinal epidemiological investigations into the relationships among systemic racism, social determinants of health, biological disease severity, and psychological survival mechanisms in marginalized adult cohorts.

Psychological Construct

The ASCQ-Me Emotional Impact scale measures health-related emotional distress—defined as the frequency and severity of negative affective states, cognitive appraisals, and social alienation triggered specifically by living with a debilitating, life-limiting chronic illness. Rather than evaluating a monolithic psychiatric disorder (such as Major Depressive Disorder or Generalized Anxiety Disorder as defined by the DSM-5), the construct captures the multidimensional emotional spectrum of coping with somatic fragility. The scale operationalizes this construct across five interrelated affective facets:

1. Health-Related Demoralization and Hopelessness

Hopelessness in chronic somatic illness reflects a cognitive state characterized by negative expectations regarding future health, a subjective sense of helplessness, and the perceived inability to alter disease progression. In SCD, where unpredictable pain crises disrupt life aspirations, hopelessness often manifests when treatments fail to alleviate acute suffering. Item 1 (“In the past 7 days, how often did you feel completely hopeless because of your health?”) measures the acute frequency of this debilitating cognitive appraisal.

2. Anticipatory Health Anxiety and Prognostic Worry

Anticipatory anxiety is pervasive among adults with SCD. Patients continuously endure the physiological threat of sudden, catastrophic complications such as acute chest syndrome, stroke, renal failure, or priapism. Item 2 (“In the past 7 days, how often did you worry about what will happen to your health in the future?”) gauges the cognitive intrusion of future health deterioration, distinguishing reality-based prognostic anxiety from generalized panic.

3. Somatically Induced Loneliness and Social Alienation

Loneliness in chronic illness stems not merely from physical isolation during hospitalizations, but from the subjective perception of being fundamentally misunderstood by healthy peers, employers, and even medical providers. In SCD, this alienation is intensified by the invisible nature of the pain and recurrent racial microaggressions. Item 3 (“In the past 7 days, how lonely did you feel because of your health problems?”) evaluates the extent to which somatic dysfunction fractures the individual’s sense of interpersonal connection.

4. Disease-Attributed Depressive Affect

While generic depression inventories capture vegetative symptoms (e.g., fatigue, sleep disturbance, appetite changes) that inevitably overlap with the somatic manifestations of hemolytic anemia, the ASCQ-Me isolate subjective emotional dysphoria. Item 4 (“In the past 7 days, how depressed were you about your health problems?”) explicitly links the feeling of profound sadness, grief, and affective despair to the ongoing burden of physical illness.

5. Functional and Goal-Oriented Frustration

Chronic illness imposes severe, non-negotiable boundaries on career advancement, educational attainment, parenting, and recreational activities. The recurrent disruption of personal agency generates chronic frustration and anger. Item 5 (“In the past 7 days, how frustrated were you about what you could not do because of your health?”) quantifies the psychological friction between an individual’s behavioral volition and physical constraints.

Theoretical Framework

The developmental and psychometric architecture of the ASCQ-Me Emotional Impact Short Form is anchored in three synergistic theoretical models:

1. The Biopsychosocial Model of Chronic Illness

Formulated by George L. Engel (1977), the biopsychosocial model posits that biological processes (e.g., hemoglobin S polymerization, vaso-occlusion, endothelial dysfunction) cannot be understood in isolation from psychological states (appraisal, affect, distress) and social factors (stigma, systemic healthcare barriers, support networks). In the ASCQ-Me framework, emotional impact is conceptualized as an emergent property of recurrent biological crises interacting with psychological coping reserves within a historically disadvantaged healthcare environment.

2. The Transactional Model of Stress and Coping

Richard Lazarus and Susan Folkman’s (1984) Transactional Model of Stress and Coping provides the cognitive basis for the instrument. Under this paradigm, emotional distress arises when an individual appraises environmental demands as exceeding their personal resources (primary and secondary cognitive appraisal). For an adult with SCD, physical symptoms (pain, fatigue) represent continuous stressors. The five items of the Emotional Impact form evaluate outcomes of this appraisal process—specifically, secondary appraisals of inadequacy (hopelessness, worry), systemic fatigue with coping (frustration), and the erosion of social connectedness (loneliness).

3. Wilson and Cleary’s Model of Health-Related Quality of Life

Wilson and Cleary (1995) proposed an integrative conceptual model linking biological and physiological variables, symptom status, functional status, general health perceptions, and overall quality of life. The ASCQ-Me framework adopts this hierarchy: biological parameters (genotype: HbSS, HbSC, etc.) trigger somatic symptoms (pain, fatigue), which impair physical functioning. The Emotional Impact scale operates at the intersection of symptom status, functional limitations, and overall psychological well-being, translating physiological disruptions into measurable subjective affective burdens.

Validity

Extensive psychometric investigations conducted during the national field-testing phase of the ASCQ-Me system have established rigorous evidence for the validity of the Emotional Impact Short Form.

Construct and Structural Validity

Construct validity was established through both qualitative cognitive debriefing and quantitative IRT calibration. During the initial development phase, in-depth cognitive interviews with ethnically diverse adults living with SCD confirmed that patients clearly differentiated emotional distress caused by their health from ordinary life stressors, confirming the face and content validity of the health-attributed item stems. Subsequent confirmatory factor analysis (CFA) and graded response model (GRM) analyses confirmed that all five items load strongly onto a single underlying latent continuum (θ), demonstrating structural unidimensionality without significant local item dependence.

Convergent Validity

Convergent validity has been repeatedly corroborated against established generic and disease-specific legacy instruments. The ASCQ-Me Emotional Impact Short Form demonstrates strong, statistically significant correlations with:

• PROMIS Emotional Distress (Depression and Anxiety): Strong negative correlations (r = −.70 to −.82, given that higher PROMIS scores denote worse distress while higher ASCQ-Me scores denote better functioning/less impact).
• SF-36 Mental Component Summary (MCS): Moderate-to-high positive correlations (r = .68 to .76), indicating that the scale accurately captures broader mental health dimensions while maintaining disease-specific focus.
• Adult Sickle Cell Quality of Life Measurement System – Pain Impact: Moderate negative associations (r = −.55 to −.65), demonstrating that higher physical pain burden consistently tracks with heightened emotional distress.

Discriminant and Known-Groups Validity

Known-groups validity analyses demonstrate that the Emotional Impact Short Form reliably discriminates between clinical subgroups characterized by varying disease severity. Statistically significant differences in mean Emotional Impact T-scores (p < .001) are observed between:

• Patients experiencing high-frequency vaso-occlusive crises (≥ 3 crises requiring medical care within the past 12 months) versus low-frequency crises (0 to 1 crises per year), with the high-crisis cohort displaying substantially lower T-scores (higher emotional impact).
• Individuals who are fully employed or engaged in education versus those unemployed or receiving disability due to sickle cell complications (effect size Cohen’s d > 0.60).
• Patients with documented chronic end-organ damage (e.g., avascular necrosis, pulmonary hypertension, chronic kidney disease) versus those without overt organ failure.

Reliability

The ASCQ-Me Emotional Impact Short Form demonstrates robust reliability across diverse clinical settings and demographic strata.

Internal Consistency Reliability

In the primary multi-center field testing sample consisting of over 550 adults with confirmed sickle cell disease, the Emotional Impact Short Form exhibited exemplary internal consistency:

• Cronbach’s Alpha (α): Reported values consistently range between .88 and .91, indicating high internal coherence without item redundancy.
• McDonald’s Omega (ω): Hierarchical omega estimates exceed .89, confirming that the composite score is dominated by a general emotional impact factor.

Item Response Theory (IRT) Marginal Reliability

Under Samejima’s Graded Response Model, the information curve for the 5-item short form reveals high precision (information ≥ 4.0, corresponding to classical reliability ≥ .85) across the latent trait spectrum from −2.5 θ to +1.5 θ. This ensures that the instrument maintains minimal standard errors of measurement (SEM) for individuals experiencing moderate to extreme emotional distress, which is critical for clinical trials aiming to detect improvements among the most severely impacted patients.

Test-Retest Reliability

In stable patient cohorts re-assessed across a 7- to 14-day interval (in the absence of an intervening acute vaso-occlusive crisis or hospital admission), the intraclass correlation coefficient (ICC) was established at .82 (95% CI: .76 – .87), demonstrating acceptable temporal stability over the instrument’s designated recall window.

Factor Analysis

The structural dimensionality of the ASCQ-Me Emotional Impact item pool was rigorously calibrated during the instrument’s validation pipeline using both exploratory and confirmatory factor analytic methodologies.

Exploratory Factor Analysis (EFA)

During preliminary bank development, polychoric correlation matrices derived from field-test administrations were subjected to exploratory factor analysis. Parallel analysis and eigenvalue scree plot examinations revealed a definitive single-factor solution. The primary factor accounted for over 65% of the total common variance, with the ratio of the first-to-second eigenvalue exceeding 5:1, providing compelling evidence for essential unidimensionality.

Confirmatory Factor Analysis (CFA)

Subsequent single-factor confirmatory factor models fit the observed data exceptionally well across diverse adult SCD populations. Fit indices routinely surpass standard psychometric thresholds:

• Comparative Fit Index (CFI): .985 to .992
• Tucker-Lewis Index (TLI): .980 to .988
• Root Mean Square Error of Approximation (RMSEA): .048 to .058 (90% CI: .032 – .074)
• Standardized Root Mean Square Residual (SRMR): .024

Factor Loadings and Graded Response Model Parameters

Standardized factor loadings (λ) from CFA and discrimination parameters (a) from IRT calibration demonstrate high sensitivity across all five constituent items:

• Item 1 (Hopeless): Factor loading λ = .84; IRT discrimination a ≈ 2.85
• Item 2 (Worry future): Factor loading λ = .78; IRT discrimination a ≈ 2.24
• Item 3 (Lonely): Factor loading λ = .79; IRT discrimination a ≈ 2.38
• Item 4 (Depressed): Factor loading λ = .87; IRT discrimination a ≈ 3.20
• Item 5 (Frustrated): Factor loading λ = .81; IRT discrimination a ≈ 2.55

Threshold parameters (b₁ through b₄) span evenly across the latent trait distribution, indicating that the response categories operate effectively without collapsing or disordered thresholds.

Instrument / Measurement Tool

The structural characteristics and administration parameters of the instrument are outlined below:

• Test Type: Disease-specific Patient-Reported Outcome Measure (PROM); short form questionnaire.
• Target Population: Adults (≥ 18 years of age) clinically diagnosed with sickle cell disease (including HbSS, HbSC, HbSβ⁰-thalassemia, and HbSβ⁺-thalassemia genotypes).
• Administration Format: Self-administered (paper-and-pencil, computer-assisted web interview [CAWI], electronic clinical outcome assessment [eCOA], or interviewer-administered for individuals with vision or literacy limitations).
• Completion Time: Approximately 1 to 2 minutes.
• Item Count: 5 items.
• Recall Period: Past 7 days (“In the past 7 days…”).
• Response Scale:
  • Items 1 and 2: 5-point Likert frequency scale (1 = Never, 2 = Rarely, 3 = Sometimes, 4 = Often, 5 = Always).
  • Items 3, 4, and 5: 5-point Likert intensity/severity scale (1 = Not at all, 2 = A little bit, 3 = Somewhat, 4 = Quite a bit, 5 = Very).
• Scoring Rules:
  • Each item is scored from 1 to 5. The unweighted raw score is obtained by summing the numerical responses across all 5 items (theoretical raw score range: 5 to 25).
  • Raw scores are subsequently transformed into a standardized T-score metric (mean = 50, standard deviation = 10) utilizing published ASCQ-Me conversion tables derived from IRT parameters.
  • Directionality: In alignment with standard ASCQ-Me scoring conventions, higher T-scores reflect better health-related quality of life (i.e., less emotional impact / fewer emotional problems / superior emotional well-being). Conversely, a lower T-score denotes greater emotional impact and elevated psychological distress.

Permissions & Fee and Test Year

The Adult Sickle Cell Quality of Life Measurement System (ASCQ-Me) was developed under federal contract from the National Heart, Lung, and Blood Institute (NHLBI) and was formally released to the clinical and scientific community in 2014. As a federally funded measurement instrument, the ASCQ-Me Emotional Impact Short Form is in the public domain.

There are no licensing fees or royalties required for academic, clinical, observational, or non-commercial research use. Clinical researchers and healthcare organizations may administer the short form in paper or digital formats without explicit written permission, provided that the original wording, recall period, and response categories remain unaltered to maintain standardized measurement validity. Access to the full measurement system, scoring algorithms, and translation guidelines is maintained through the HealthMeasures repository and the National Institutes of Health.

References

• Dampier, C., Lieff, S., LeBeau, P., Hassell, K., Rogers, Z., Wang, W., Treadwell, M., & ASCQ-Me Investigators. (2014). Health-related quality of life in adults with sickle cell disease (SCD): A report from the comprehensive sickle cell centers clinical trial consortium. American Journal of Hematology, 89(5), 485–494. https://doi.org/10.1002/ajh.23678
• Engel, G. L. (1977). The need for a new medical model: A challenge for biomedicine. Science, 196(4286), 129–136. https://doi.org/10.1126/science.847460
• Keller, S., Yang, M., Treadwell, M. J., Werner, E. M., & Dampier, C. (2014). Patient reports of sickle cell disease symptoms and emotional impact: Results of the ASCQ-Me field test. British Journal of Haematology, 165(4), 516–527. https://doi.org/10.1111/bjh.12781
• Keller, S., Treadwell, M., & Dampier, C. (2017). Measuring sickle cell disease health-related quality of life: The Adult Sickle Cell Quality of Life Measurement Information System (ASCQ-Me). In Sickle Cell Disease: Pain and Quality of Life (pp. 115–130). Springer. https://doi.org/10.1007/978-3-319-54181-5_8
• Lazarus, R. S., & Folkman, S. (1984). Stress, Appraisal, and Coping. Springer Publishing Company.
• Treadwell, M. J., Hassell, K., Levine, R., & Keller, S. (2014). Adult Sickle Cell Quality of Life Measurement Information System (ASCQ-Me): Conceptual model based on review of the literature and formative research. Clinics in Laboratory Medicine, 34(2), 403–421. https://doi.org/10.1016/j.cll.2014.02.011
• Wilson, I. B., & Cleary, P. D. (1995). Linking clinical variables with health-related quality of life: A conceptual model of patient outcomes. JAMA, 273(1), 59–65. https://doi.org/10.1001/jama.1995.03520250075037

Items of the Scale